Mechanisms of Antidepressant Non-Response in Late-Life Depression

New York State Psychiatric Institute

Status: Completed

Conditions: Major Depressive Disorder

Treatments: Drug: Escitalopram; Drug: Placebo oral tablet

Study type: Interventional

Funder types: Other

Identifiers

NCT01931202

6836

Details and patient eligibility

About

This project seeks to elucidate the mechanisms by which antidepressant medications have limited efficacy in Late Life Depression (LLD) in order to develop new treatment interventions for this prevalent and disabling illness. Investigators hypothesize that the presence of executive dysfunction (ED),which is common in depressed adults over 60, impairs the ability to form appropriate expectancies of improvement with antidepressant treatment. Greater expectancy has been shown to improve antidepressant treatment outcome and is hypothesized to be a primary mechanism of placebo effects. Moreover, white matter hyperintensities (WMH) on magnetic resonance imaging (MRI) are more prevalent in patients with LLD compared to healthy controls. It has been argued that WMH contribute to the pathogenesis of LLD with ED and decrease the efficacy of antidepressant medications by disrupting connections between prefrontal cortical (PFC) and subcortical structures. Vascular lesions to white matter tracts may also compromise the pathway by which expectancy-based placebo effects influence depressive symptoms. Expectancies reflect activation in PFC areas that may improve depressive symptoms by modulating the activity of subcortical regions subserving negative affective systems (i.e., amygdala) as well as those important in reward and hedonic capacity (nucleus accumbens and ventral striatum). Thus, LLD patients with ED and WMH may sustain a "double-hit" to their ability to experience placebo effects in antidepressant treatments: ED diminishes the ability to generate appropriate treatment expectancies, while WMH disrupt the physiologic pathways by which expectancies lead to improvement in depressive symptoms.

Full description

To determine whether decreased antidepressant medication response in LLD patients with ED and WMH is caused by a loss of expectancy effects, Investigators will evaluate 130 outpatients with LLD at baseline to determine their degree of ED (interference score on Stroop Color-Word Test), WMH burden (severity score on Fazekas modified Coffey Rating Scale derived from anatomical MRI), and white matter tract integrity (using diffusion tensor imaging [DTI]). Building on work from the investigators K23 Award, the investigator will manipulate participants' expectancy of improvement in an 8-week duration antidepressant trial by randomizing patients between open administration of escitalopram (i.e., high expectancy) and placebo-controlled administration of escitalopram (i.e., low expectancy). The difference in antidepressant response observed between open and placebo-controlled medication treatment is a measure of the expectancy contribution to outcome, which is substantial in younger depressed adults but investigators hypothesize this will be diminished in LLD patients with ED and WMH.

Enrollment: 138 patients

Sex: All

Ages: 60 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women aged 60-90 years
• Diagnosis with nonpsychotic Diagnostic and Statistical Manual (DSM) IV MDD
• 24-item Hamilton Rating Scale for Depression (HRSD) score ≥ 16
• Willing to and capable of providing informed consent and complying with study procedures

Exclusion criteria

• Current comorbid Axis I DSM IV disorder other than Nicotine Dependence, Adjustment Disorder, or Anxiety Disorder
• diagnosis of substance abuse or dependence (excluding Nicotine Dependence) within the past 12 months
• History of psychosis, psychotic disorder, mania, or bipolar disorder
• Diagnosis of probable Alzheimer's Disease, Vascular Dementia, or Parkinson's Disease
• MMSE < 24
• HRSD suicide item > 2 or Clinical Global Impressions (CGI)-Severity score of 7 at baseline
• history of allergic or adverse reaction to escitalopram, or non-response to adequate trial of escitalopram (at least 4 weeks at dose of 20mg) during the current episode
• current treatment with psychotherapy, antidepressants, antipsychotics, or mood stabilizers
• having contraindication to MRI scanning (such as metal in body) or unable to tolerate the scanning procedures (i.e., severe obesity, claustrophobia)
• acute, severe, or unstable medical or neurological illness

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

138 participants in 3 patient groups, including a placebo group

Double Blind-Placebo

Placebo Comparator group

Description:

Blinded treatment with placebo, one pill a day. If after the 4 weeks, the patient has not remitted, they will be increased to 2 pills a day.

Treatment:

Drug: Placebo oral tablet

Double Blind-Escitalopram

Active Comparator group

Description:

Blinded treatment with either escitalopram 10mg, increased to escitalopram 20mg at week 4 if depression has not remitted.

Treatment:

Drug: Escitalopram

Open Treatment with Escitalopram

Active Comparator group

Description:

Open treatment with 10mg of escitalopram, increased to 20mg if depression has not remitted at week 4.

Treatment:

Drug: Escitalopram